- Home
- CVKD vs NRSN Comparison
CVKD vs NRSN Comparison
Compare CVKD & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVKD
- NRSN
- Stock Information
- Founded
- CVKD 2022
- NRSN 2017
- Country
- CVKD United States
- NRSN Israel
- Employees
- CVKD N/A
- NRSN N/A
- Industry
- CVKD Medicinal Chemicals and Botanical Products
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- CVKD Health Care
- NRSN Health Care
- Exchange
- CVKD Nasdaq
- NRSN Nasdaq
- Market Cap
- CVKD 31.5M
- NRSN 26.0M
- IPO Year
- CVKD 2023
- NRSN 2021
- Fundamental
- Price
- CVKD $16.75
- NRSN $1.03
- Analyst Decision
- CVKD Strong Buy
- NRSN Hold
- Analyst Count
- CVKD 1
- NRSN 1
- Target Price
- CVKD $32.00
- NRSN N/A
- AVG Volume (30 Days)
- CVKD 22.9K
- NRSN 135.5K
- Earning Date
- CVKD 05-08-2025
- NRSN 04-07-2025
- Dividend Yield
- CVKD N/A
- NRSN N/A
- EPS Growth
- CVKD N/A
- NRSN N/A
- EPS
- CVKD N/A
- NRSN N/A
- Revenue
- CVKD N/A
- NRSN N/A
- Revenue This Year
- CVKD N/A
- NRSN N/A
- Revenue Next Year
- CVKD N/A
- NRSN N/A
- P/E Ratio
- CVKD N/A
- NRSN N/A
- Revenue Growth
- CVKD N/A
- NRSN N/A
- 52 Week Low
- CVKD $5.70
- NRSN $0.51
- 52 Week High
- CVKD $22.90
- NRSN $1.73
- Technical
- Relative Strength Index (RSI)
- CVKD 49.23
- NRSN 49.96
- Support Level
- CVKD $14.10
- NRSN $1.00
- Resistance Level
- CVKD $17.39
- NRSN $1.04
- Average True Range (ATR)
- CVKD 1.57
- NRSN 0.09
- MACD
- CVKD 0.04
- NRSN 0.01
- Stochastic Oscillator
- CVKD 54.19
- NRSN 76.25
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.